Literature DB >> 2530468

[3H]5-hydroxytryptamine binding sites in postmortem human brain.

S C Cheetham1, Y Yamaguchi, R W Horton.   

Abstract

Binding sites for [3H]5-hydroxytryptamine (5-HT) in postmortem human frontal cortex, hippocampus and amygdala were studied by displacement with 5-HT selective drugs. The results demonstrated the selective labelling of 5-HT1-like sites by [3H]5-HT in the cortex, with little or no labelling of 5-HT2 or 5-HT3 sites. Self-displacement of the binding of [3H]5-HT is consistent with the presence of a single population of sites, indicating that 5-HT is non-selective for the 5-HT1 subtypes. Around 40% of the 5-HT1 sites in the frontal cortex and amygdala were of the 5-HT1A subtype, in contrast to 60% in the hippocampus. The drug RU 24969 consistently displaced with, a high affinity, a greater proportion of [3H]5-HT sites than did 8-OH-DPAT in all three regions of the brain. The nature of these additional sites was not established. A small proportion (less than 10%) of [3H]5-HT sites in the frontal cortex appeared to be of the 5-HT1C subtype, as these sites were displaced with high affinity by mianserin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530468     DOI: 10.1016/0028-3908(89)90117-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  2 in total

1.  Brain 5-HT1 binding sites in depressed suicides.

Authors:  S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.

Authors:  James D Sexton; Charles D Nichols; Peter S Hendricks
Journal:  Front Psychiatry       Date:  2020-02-11       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.